Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.01 USD
Change Today -0.40 / -1.57%
Volume 110.9K
SGNT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 12:51 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Open
$25.34
Previous Close
$25.41
Day High
$25.36
Day Low
$24.78
52 Week High
10/14/14 - $33.60
52 Week Low
03/26/15 - $21.84
Market Cap
803.2M
Average Volume 10 Days
323.6K
EPS TTM
$1.12
Shares Outstanding
32.1M
EX-Date
--
P/E TM
22.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGENT PHARMACEUTICALS INC (SGNT)

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers, such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis; and Propofol, a sedative used to induce and maintain general anesthesia during surgical procedures. As of December 31, 2014, its product portfolio included 54 marketed products. Sagent Pharmaceuticals, Inc. sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

466 Employees
Last Reported Date: 03/16/15
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

President, Chief Legal Officer and Corporate ...
Total Annual Compensation: $328.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $344.8K
Executive Vice President of National Accounts...
Total Annual Compensation: $297.1K
Compensation as of Fiscal Year 2014.

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year 2015

Sagent Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s net revenue was $82.6 million, an increase of $11.8 million, or 17%, compared to $70.9 million in the first quarter of 2014. The increase was driven primarily by the $7.4 million from the addition of Omega on October 1, 2014. Net loss of $1.9 million or diluted loss per share of $0.06, inclusive of $3.1 million ($0.10 per share) of costs related to management transition, acquisition-related costs and the inventory step up on Omega, net of tax. Adjusted EBITDA was $9.0 million, a decline of $0.5 million, or 6% compared to $9.6 million in the first quarter of 2014. Loss from operations was $189,000 compared to income from operations of $6,632,000 a year ago. Loss before income taxes was $1,575,000 compared to income before income taxes of $6,333,000 a year ago. EBITDA was $1,803,000 compared to $8,358,000 a year ago. For the year 2015, the company expected net revenue to be in the range of $325 to $375 million. The company anticipates adjusted EBITDA in the range of $20 to $50 million. The company expected EBITDA to be in the range of $11 million to $39 million. Expected net income to be in the range of $3 million loss to $13 million earnings. Adjusted gross profit will be in the range of 27% to 31%.

Sagent Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2015

Sagent Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2015., at 08:00 Central Standard Time. Location: The Stonegate Conference and Banquet Centre. Agenda: To elect as Class I and Class III directors the nominees named in the Proxy Statement; to ratify the retention of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; to an advisory vote to approve the compensation of the named executive officers; and to transact any other business properly presented at the meeting or any adjournment thereof.

Sagent Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 05, 2015

Sagent Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $25.01 USD -0.40

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $15.74 USD -0.095
Pernix Therapeutics Holdings Inc $4.82 USD -0.03
Pfizer Ltd/India 2,122 INR -12.90
SciClone Pharmaceuticals Inc $9.22 USD +0.155
Sucampo Pharmaceuticals Inc $21.30 USD -0.09
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 25.3x
Price/Sales 2.7x
Price/Book 3.0x
Price/Cash Flow 24.9x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.